Loading
NASDAQHealthcareBiotechnology
Latest quote
$14.56
+$0.57 · +4.07%
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Regular session
$14.56
+$0.57 · +4.07%
Regular session · ET · Market data may be delayed.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Day range
Current $14.56
52-week range
Current $14.56
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
57
Fair Value
Sentiment
56
Mixed
Risk
45
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Day range
Current $14.56
52-week range
Current $14.56
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 |
|---|---|---|
| Revenue | 31.89M USD | 20.46M USD |
| Gross profit | 31.89M USD | 20.46M USD |
| Research and development | 224.7M USD | 175.31M USD |
| Selling, general, and administrative | 42.26M USD | 42.09M USD |
| Operating expenses | 266.96M USD | 217.4M USD |
| Interest income | 13.66M USD | 18.12M USD |
| Interest expense | 1.14M USD | 2.12M USD |
| Depreciation and amortization | 13.18M USD | 15.35M USD |
| Operating income | −235.07M USD | −196.94M USD |
| Net income | −203.15M USD | −173.77M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$26.00
78.57% upsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG21.99M1.07%1.56B USD0.75%$51.46+4.40%
Vanguard Morningstar Total Stock Market ETFVTI12.47M0.00%2.3T USD0.03%$381.72+0.57%
iShares Russell 2000 ETFIWM9.06M0.01%77.7B USD0.19%$278.9+0.48%
Vanguard Extended Market ETFVXF4.59M0.00%95.4B USD0.05%$234.66+0.65%
JPMorgan U.S. Tech Leaders ETFJTEK3.9M0.08%4.8B USD0.65%$107.54+1.45%
ALPS Medical Breakthroughs ETFSBIO2.28M1.22%187.46M USD0.50%$55.47+2.83%
iShares Russell 2000 Growth ETFIWO2.2M0.02%14.04B USD0.24%$356.75+0.93%
Vanguard Russell 2000 ETFVTWO2.15M0.01%18B USD0.06%$112.65+0.49%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFJPMorgan U.S. Tech Leaders ETFJTEKALPS Medical Breakthroughs ETFSBIOiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
